Cryopyrin-Associated Periodic Syndromes clinical trials
The registry lists 35 studies for Cryopyrin-Associated Periodic Syndromes across more than 10 countries. 5 are recruiting or about to start. 31 of them are mainly about Cryopyrin-Associated Periodic Syndromes (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-09.
Get an email when these change. Save the Cryopyrin-Associated Periodic Syndromes studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis Pharmaceuticals (10) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3) · Novartis (2) · Handok Inc. (2) · Zydus Lifesciences Limited (1) · Aclaris Therapeutics, Inc. (1) · Charite University, Berlin, Germany (1)
What is being tested here
Drugs under test in Cryopyrin-Associated Periodic Syndromes studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Who these studies take
Of the 4 Cryopyrin-Associated Periodic Syndromes studies recruiting now, 1 (25%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (75%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (50%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (75%) | 3 (75%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 4 (100%) | 4 (100%) |
| 85 | 4 (100%) | 4 (100%) |
Across all 35 studies, recruiting or not: 31% stop at 75 or younger and 17% at 65; 57% take children; 0% are for women only and 3% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 35 of 35. search them.
- Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)RecruitingNCT029745951 country
- Ilaris NIS in KoreaRecruitingNCT068381431 country
- Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid LoadRecruitingNCT06974877Phase 11 country
- Circadian Rhythm Deregulation in Patients With CAPSRecruitingNCT06544018Not applicable1 country
- Are Mast Cells Involved in Autoinflammatory DiseasesNot yet recruitingNCT052927681 country
- Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)CompletedNCT07247266Phase 11 country
- Pathogenesis of Physical Induced Urticarial SyndromesCompletedNCT008879391 country
- A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic SyndromeCompletedNCT05812781Phase 21 country
- Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)CompletedNCT04868968Phase 23 countries
- Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)TerminatedNCT04524858Phase 21 country
- Adult Outcomes of Children With CAPSCompletedNCT048565401 country
- The Use of Kineret (Anakinra) in the Treatment of Familial Cold UrticariaCompletedNCT00214851Phase 11 country
- Does the Cap Increase the Finding of Polyps When Water Exchange Colonoscopy is UsedStatus unknownNCT03566615Not applicable4 countries
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)CompletedNCT05186051Phase 21 country
- Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory DiseaseTerminatedNCT00770601Phase 31 country
- Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension PhaseCompletedNCT00991146Phase 31 country
- A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 StudiesCompletedNCT02334748Phase 31 country
- Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334CompletedNCT04086602Phase 11 country
- Kineret CAPS Post Authorisation StudyCompletedNCT023263762 countries
- A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)Status unknownNCT03923140Phase 21 country
- Adenoma Detection Rate in Colonoscopy Performed With EndoRingsTerminatedNCT03219918Not applicable1 country
- Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT01576367Phase 37 countries
- Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells SyndromeCompletedNCT00465985Phase 36 countries
- A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's DiseaseWithdrawnNCT01211977Phase 1/21 country
- Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT01302860Phase 37 countries
- The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in CanadaCompletedNCT01105507Phase 31 country
- HL2351 CAPS Phase II StudyTerminatedNCT02853084Phase 21 country
- Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory DiseaseTerminatedNCT00069329Phase 1/21 country
- Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory DiseaseCompletedNCT00685373Phase 39 countries
- Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) PatientsCompletedNCT012136415 countries
- A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation StudyCompletedNCT02175056Phase 11 country
- Interleukin-1 Trap to Treat Autoinflammatory DiseasesCompletedNCT00094900Phase 21 country
- Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)CompletedNCT01045772Phase 21 country
- Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)CompletedNCT00288704Phase 31 country
- Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical SymptomsCompletedNCT00487708Phase 25 countries